Seltorexant
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Seltorexant
- Molecular weight
- 407.45
- Structure (SMILES)
- Cc1cc(C)nc(N2CC3CN(C(=O)c4c(F)cccc4-n4nccn4)CC3C2)n1
- ((3AR,6AS)-5-(4,6-DIMETHYLPYRIMIDIN- 2-YL)HEXAHYDROPYRROLO(3,4-C)PYRROL-2(1H)-YL)(2-FLUORO- 6-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE OREXIN RECEPTOR ANTAGONIST
- 3ar 6as 5 4 6 dimethylpyrimidin 2 yl hexahydropyrrolo 3 4 c pyrrol 2 1h yl 2 fluoro 6 2h 1 2 3 triazol 2 yl phenyl methanone orexin receptor antagonist
- jnj 42847922
- jnj 42847922 10 mg
- jnj 42847922 20 mg
- jnj 42847922 20mg
- jnj 42847922 40 mg
- jnj 42847922 40mg
- jnj 42847922 5 mg
- JNJ-42847922
- JNJ-42847922 20mg
- JNJ-42847922 40mg
- methanone 3ar 6as 5 4 6 dimethyl 2 pyrimidinyl hexahydropyrrolo 3 4 c pyrrol 2 1h yl 2 fluoro 6 2h 1 2 3 triazol 2 yl phenyl rel
- METHANONE, ((3AR,6AS)-5-(4,6-DIMETHYL-2-PYRIMIDINYL)HEXAHYDROPYRROLO(3,4-C)PYRROL-2(1H)-YL)(2-FLUORO-6-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)-, REL-
- min 202
- MIN-202
- seltorexant
- Seltorexant
- seltorexant [INN]
- SELTOREXANT [USAN]
- Seltorexant [WHO-DD]
- seltorexant 20 mg
- Seltorexant 20 mg
- seltorexant 40 mg
- Seltorexant 40 mg
And 3 more, listed on the interactive page.
- CAS registry numbers
- 1452539-75-1
- ChEMBL ID
- CHEMBL3597971
- InChIKey
- SQOCEMCKYDVLMM-UHFFFAOYSA-N
- FDA ingredient codes (UNII)
- AIS8N3O50B
- 67116280
- 86278359
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- seltorexant
- Type
- Synthetic organic
- Action
- Antagonist
- Action type
- Antagonist
- Target
- OX1 receptor
- Gene symbol
- HCRTR1
- Protein identifier
- O43613
- Median affinity
- 6.3
- Affinity units
- pKB
- Action
- Antagonist
- Action type
- Antagonist
- Target
- OX1 receptor
- Gene symbol
- HCRTR1
- Protein identifier
- O43613
- Median affinity
- 6.1
- Affinity units
- pKi
- Action
- Antagonist
- Action type
- Antagonist
- Target
- OX2 receptor
- Gene symbol
- HCRTR2
- Protein identifier
- O43614
- Median affinity
- 8.8
- Affinity units
- pKB
- Action
- Antagonist
- Action type
- Antagonist
- Target
- OX2 receptor
- Gene symbol
- HCRTR2
- Protein identifier
- O43614
- Median affinity
- 8
- Affinity units
- pKi
- Primary target
- Yes
- Mechanism
- Orexin receptor 2 antagonist
- Action type
- Antagonist
- Target
- Orexin receptor type 2
- Protein identifier
- O43614
Open Targets mechanisms
- Mechanism
- Orexin receptor 2 antagonist
- Action type
- Antagonist
- Target
- Orexin receptor type 2
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Depressive Disorder, Major
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003761
- Subject identifier
- D003865
- Condition
- Sleep Apnea, Obstructive
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003918
- Subject identifier
- D020181
- Condition
- Sleep Initiation and Maintenance Disorders
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004698
- Subject identifier
- D007319
- Condition
- Depressive Disorder, Major
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0002009
- Subject identifier
- D003865
- Condition
- Alzheimer Disease
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004975
- Subject identifier
- D000544
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003918
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004698
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002009
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004975
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007147
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0013600
- Highest recorded phase
- 3
- NCT02067299
- NCT02476058
- NCT03227224
- NCT03321526
- NCT03374475
- NCT04451187
- NCT04513912
- NCT02464046
- NCT03375203
- NCT03796026
- NCT04532749
- NCT04533529
- NCT04951609
- NCT04616677
- NCT04960124
- NCT05307692
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 0
- Polar surface area
- 80.04
- Calculated partition coefficient (ALogP)
- 2.02
- Calculated partition coefficient (XLogP)
- 2.8
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 30
- Molecular formula
- C21H22FN7O
- Monoisotopic mass
- 407.18698651
- Natural product
- No
- Recorded assays
- 116
- Active assays
- 29
- Confirmatory
- Other
These details could not be displayed.
Related records
Trials (34)
- A Drug Interaction Study in Healthy Participants to Assess the Effect of Rifampin on the Pharmacokinetics of JNJ-42847922
- A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder
- A Study of JNJ-42847922 (Seltorexant) in Healthy Participants
- A Study of Oral Seltorexant as an add-on Medication to an Antidepressant on On-road Driving Performance in Participants With Major Depressive Disorder
- A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Participants
- A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy
- A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant
- A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
- A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
- A Study of Seltorexant in Healthy Participants
- A Study of Seltorexant in Participants With Probable Alzheimer's Disease
- A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants
- A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea
- A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults
- A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
- A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem
- A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants
- A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult Participants
- A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants
In development for (6)
- Alzheimer disease Phase 2
- Insomnia Phase 2
- Kidney disorder Phase 1
- Liver disorder Phase 1
- Major depressive disorder Phase 3
- Obstructive sleep apnea syndrome Phase 1